Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment
Autor: | Jiri Frohlich, Allan D. Sniderman, Anthony C Keech, J. E. Roeters Van Lennep, C. D. Furberg, Ana M. Wägner, Ingmar Jungner, Göran Walldius |
---|---|
Rok vydání: | 2003 |
Předmět: |
medicine.medical_specialty
Apolipoprotein B Coronary Artery Disease Coronary artery disease chemistry.chemical_compound Risk Factors Internal medicine medicine Humans Pharmacology (medical) Apolipoproteins B Ldl cholesterol biology Cholesterol Vascular disease business.industry Anticholesteremic Agents Cholesterol LDL General Medicine Statin treatment medicine.disease Pathophysiology Endocrinology chemistry Coronary risk Cardiology biology.protein lipids (amino acids peptides and proteins) Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business |
Zdroj: | The Lancet. 361:777-780 |
ISSN: | 0140-6736 |
Popis: | More Nobel prizes have been awarded for the study of cholesterol than for any other molecule. Presently, concentration of LDL cholesterol is the fundamental index of risk of vascular disease. It is an estimate of the mass of cholesterol in the LDL fraction in plasma. By contrast, the value for apolipoprotein B is a measurement of the total number of atherogenic particles. Results of many studies show that apolipoprotein B is a better marker of risk of vascular disease and a better guide to the adequacy of statin treatment than any cholesterol index. Moreover, the ratio of apolipoprotein B/apolipoprotein A-1 seems superior to the ratio of total cholesterol/HDL cholesterol as an overall index of the risk of vascular disease. We review this evidence and include observations that were not previously published. The pathophysiological bases for the superiority of apolipoprotein B to cholesterol as a predictor of risk are reported elsewhere. 1 |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |